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 The Synechococcus elongatus COG0325 gene, pipY, functionally interacts with 
nitrogen regulatory gene pipX. As a first step towards molecular understanding of these 
interactions PipY was characterized. This 221-residue protein is monomeric and hosts 
pyridoxal phosphate (PLP), binding it with limited affinity and losing it upon D-
cycloserine incubation. PipY crystal structures with and without PLP revealed a single-
domain monomer folded as the TIM barrel of type III-fold PLP enzymes, with PLP 
highly exposed, fitting a PipY role in PLP homeostasis. The mobile PLP phosphate-
anchoring C-terminal helix might act as trigger for PLP exchange. Exploiting the 
universality of COG0325 functions, we used PipY in site-directed mutagenesis studies 
to shed light on disease causation by epilepsy-associated mutations in the human 
COG0325 gene, PROSC. 
Keywords. Synechococcus elongatus PCC7942, COG0325, pyridoxal phosphate 
proteins. 
Abbreviations. CD, circular dichroism; DCS, D-cycloserine; DTT, dithiothreitol; ODC, 
ornithine decarboxylase; PDB, Protein Data Bank; PEG, polyethylene glycol; PLP, 
pyridoxal 5'-phosphate; r.m.s.d., root-mean-square deviation    
3 
 
 Cyanobacteria, the chloroplasts ancestors [1], are very ancient, widespread and 
abundant [2] photosynthetic bacteria that play key roles in global oxygen, CO2 and 
nitrogen fluxes [3]. Nitrogen incorporation is highly regulated in cyanobacteria [4]. The 
small protein PipX [5,6] is a key player, as highlighted by transcriptomic studies in 
Synechococcus elongatus PCC7942 (from now on S. elongatus) [7]. PipX regulation, 
mediated by the carbon/energy/nitrogen signalling protein PII and the gene expression 
regulator NtcA [5,8,9], also involves newly discovered partners as PlmA [10]. 
 Very recently, the synteny in cyanobacteria of the mutually adjacent pipX and 
pipY genes led to the identification in S.elongatus of functional interactions between 
these two genes [11]. pipY is a member of the highly widespread [12] and intriguing 
COG0325 gene family [11] that includes Escherichia coli yggS, a gene that when 
inactivated causes a phenotype of pyridoxine toxicity and pleiotropic changes related to 
amino acid-related metabolism [12-14]. Inactivation of pipY in S.elongatus [11] also 
enhanced pyridoxine toxicity and led to increased sensitivity to antibiotics that target 
pyridoxal phosphate (PLP) such as D-cycloserine (DCS) [15]; these two traits were 
influenced by various amino acids [11]. Pleiotropic changes were also observed in null 
mutants of the COG0325 genes ylmE of Bacillus subtilis [16] and PROSC of humans 
[17,18]. The deficiency of the human gene was reported to cause vitamin B6-dependent 
epilepsy [17,18]. The pleiotropy of the changes associated with COG0325 mutations is 
best explained if the COG0325 products, which are PLP proteins [19], rather than being 
enzymes play key roles in PLP homeostasis. These roles remain uncharacterized 
molecularly.  
 Striving towards delineation of the roles of PipY, we decided to characterize 
physically and structurally PipY from S. elongatus. Such characterization appeared 
pertinent, given the extensive in vivo functional data collected for its corresponding 
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gene [11]. Furthermore, there was only one published analysis of the structure of 
another COG0325 protein, YBL036C from yeast [19], an organism that is 
phylogenetically distant from cyanobacteria. The YBL036C structure had been 
determined as a part of a structural genomics effort, and the biological in vivo role of 
YBL036C had not been specifically explored. In addition, the structural knowledge of 
YBL036C did not include the corresponding structure without PLP. However, the 
changes associated with the presence or absence of PLP may be highly relevant for a 
role of COG0325 proteins in PLP delivery to other targets. Although crystal structures 
of three bacterial COG0325 proteins have been deposited in the Protein Data Bank 
(PDB) (Supplementary Table S1), none of these structures has been analysed, justifying 
the need for thorough structural analysis of a bacterial COG0325 protein in the absence 
and the presence of PLP.  We carry out here such structural analysis on S. elongatus 
PipY. The detailed structural information gained in the present studies by X-ray 
crystallography of PLP-containing and PLP-free PipY makes of PipY a true structural 
paradigm for COG0325 proteins. In addition, we have characterized some PipY traits in 
solution, including its mass, its spectroscopic properties and both its ability to bind PLP 
and its sensitivity to the PLP-targeting antibiotic DCS. The toxicity of this antibiotic for 
S. elongatus was previously shown to be increased by pipY inactivation [11]. 
 We also get insight here on the effects of two PROSC mutations, Pro87Leu and 
Arg241Gln, reported in patients with vitamin B6-dependent epilepsy [17,18]. 
Puzzlingly, the clinical severity inferred for these mutations did not parallel the ability 
of the corresponding mutant PROSC gene forms to complement an E.coli yggS
-
 mutant 
for its phenotype of increased sensitivity to pyridoxine toxicity [17]. To try to explain 
these puzzling observations, we have introduced into PipY the mutations corresponding 
to Pro87Leu and Arg241Gln of PROSC, studying relevant characteristics of the mutant 
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PipY forms. This approach has exploited the apparent universality of COG0325 
functions (for which the recent studies on S. elongatus provided strong confirmation 
[11]) and the sequence conservation between S. elongatus PipY and human PROSC 
(Supplementary Fig. S1). In this way we provide valuable hints on the respective ability 
and lack of ability of the Pro87Leu and Arg241Gln PROSC mutants to override the 
mutant phenotype of the yggS
-
 E.coli mutant strain [17], as well as on the possible 
mechanism of disease causation by the Arg241Gln PROSC mutation. 
 
MATERIALS AND METHODS 
Production of wild-type and mutant PipY  
 The S.elongatus pipY open reading frame (gene Synpcc7942_2060, 
http://genome.microbedb.jp/cyanobase/GCA_000012525.1/genes/Synpcc7942_2060),  
PCR-amplified from genomic DNA using Deep Vent DNA polymerase (from New 
England Biolabs) and the primers 5'-GTCAGAGGCACATATGGCCCAAATTGC-3' 
and 5'-GGCCAAGACTCGAGCGATCGCGGC-3', was digested with NdeI/XhoI and 
ligated into the similarly digested pET-22b+ plasmid (from Novagen). The resulting 
pET-22b(+)-2060 plasmid, isolated from E.coli DH5α, was used for site-directed 
mutagenesis using the Quickchange approach (Stratagene, La Jolla, CA) and the 
following forward and reverse mutagenic primers: for the Pro63Leu mutation,    
5'ACGGATCTGCTGGATTTGACTTGG3' and 
5'AAGTCAAATCCAGCAGATCCGTCAG3'; and for the Arg210Gln mutation, 
5'GCAACTTGGATTCAAGTCGGAACC3' and 
5'TTCCGACTTGAATCCAAGTTGCC3'. The presence of the correct sequences and of 
the desired mutations was verified by Sanger sequencing of the plasmids.  
 To produce PipY with a C-terminal -GluHis6 tag, the pET-22b(+)-2060 plasmid 
was transformed into E.coli BL21(DE3) (from Novagen), growing the transformed cells 
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in 1-L liquid LB-ampicillin (0.1 mg/ml) at 37ºC, to ~0.8 OD
600
, followed by 3-hour 
induction with 1 mM isopropyl β-D-1-thiogalactopyranoside. All subsequent steps were 
at 4ºC. After centrifugation, the cell pellet, suspended in 30 ml of 25 mM HEPES pH 
7.5/0.4 M NaCl/1 mM dithiothreitol (DTT)/1 mM phenyl methyl sulphonyl fluoride/20 
mM imidazole, was sonicated to disrupt the cells, the suspension was centrifuged, and 
PipY was purified from the supernatant by Ni-affinity chromatography and imidazole 
gradient elution (His-Trap HP 1-ml column in an Åkta-FPLC, both from GE 
Healthcare). The resulting preparation was concentrated to ~10 mg/ml (Bradford assay 
[20] using bovine serum albumin as standard) and placed in 20 mM HEPES pH 7.5/16 
mM NaCl/1mM DTT (storage buffer) by centrifugal ultrafiltration (Amicon Ultra, from 
Millipore). The Pro63Leu and Arg210Gln mutants were purified in the same way. 
  
PipY crystallization, X-ray diffraction and structure determination 
 Crystals were grown by vapour-diffusion (21°C) in 0.8 μl sitting drops made of 
1/1 mixtures of protein solution and crystallization solution. The protein solution 
contained 12.6 mg/ml PipY in storage buffer supplemented with either 10 mM DCS 
(PipY-Apo) or 10 mM D-Ala (PipY-PLP). The crystallization solution was, for PipY-
Apo, 0.1 M Tris-HCl pH 8.5/0.2 M MgCl2/25% w/v polyethylene glycol (PEG) 3350; 
and for PipY-PLP, 0.1 M Hepes pH 7.5/0.2 M calcium acetate/18% w/v PEG 8000. 
Crystals were flash-frozen in liquid nitrogen using as cryobuffers the crystallization 
solutions (enriched with 5% extra PEG 3350 for PipY-Apo). Synchrotron (Table 1) X-
ray diffraction was at -170°C, using Pilatus3 6M detectors. Datasets at 1.90/1.93 Å 
resolution (PipY-Apo/PipY-PLP) were processed with XDS [21], scaled with 
AIMLESS [22], (Table 1) and phased by molecular replacement with Phaser [23], using 
for the PipY-Apo dataset a poly-alanine model of YggS from E.coli (PDB entry 1W8G) 
7 
 
lacking residues 1-20; and utilizing for PipY-PLP the A subunit of PipY-Apo once it 
was traced and refined. Refmac5 [24] was used for optimizing the positioning of the 
two PipY chains present in the asymmetric units of both crystals (Table 1), using rigid 
body refinement. It was also used for model refinement, alternating iteratively cycles of 
restrained refinement and of manual model building with Coot [25]. This last program 
was used for incorporating PLP (taken from the PDB) to the PipY-PLP model. Isotropic 
B factors and Translation/Libration/Screw (TLS) were used in the last refinement steps 
[26], choosing the TLS groups with the TLSMD server 
(http://skuld.bmsc.washington.edu/~tlsmd) [27]. All diffraction data were used 
throughout the refinement processes, except for the randomly selected 5% of the data 
used for Rfree calculation. The stereochemistry of the model was checked and improved 
with PDB_REDO [28]. Analysis with Rampage [29] of the geometry of the main chain 
torsion angles revealed excellent values for both models. Graphical representations of 
the structures were generated with PyMOL (Pymol Molecular Graphics System, 
Version 1.6, Schrödinger, LLC, www.pymol.org). 
 
Other techniques 
 Size exclusion chromatography was performed on a Superdex 200 10/300 
column fitted on an ÄKTA FPLC (both from GE Healthcare), at 0.5 ml/min flow rate, 
using a solution of 10 mM Na phosphate pH 7.0/0.4 M NaCl/5 mM MgCl2/5 mM 
EDTA/0.2 mM DTT, and monitoring the absorbance of the effluent at 280 nm. The 
mass of PipY was estimated from a semi-logarithmic plot prepared with protein 
standards of known masses.  
 Spectrophotometric determinations were carried out with a NanoDrop 1000 
spectrophotometer (Thermo Scientific) on 2 μl samples. All reagents and PipY were in 
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storage buffer. Optical absorption values are given for 1-cm light path. Incubations of 
PipY with PLP or DCS were performed for 15 min in 50 μl solutions at 25ºC, with 
controls lacking PipY carried in parallel and subtracted. For incubation with DCS, PipY 
had been incubated previously with 0.34 mM PLP and then freed from unbound PLP by 
centrifugal gel filtration [30]. Plots of the absorbance at 425 nm of PipY versus PLP or 
DCS concentrations were fitted to hyperbolae using GraphPadPrism (GraphPad 
Software, San Diego, CA). 
 CD spectra in the far-UV region (195–250 nm) were obtained at 21 °C with a 
Jasco J-810 spectropolarimeter in 0.2 ml of 50 mM Na phosphate pH 7.5 and 0.25 
mg/ml protein in a 0.1 cm-path cell. Each spectrum was the average of five scans.  
 The thermal stabilities of wild-type and mutant PipY proteins were investigated 
by the thermofluor approach [31] as previously reported [32], using 0.25 mg/ml PipY in 
a solution of 22 mM Hepes pH 7.5 with the indicated additions. 
  
RESULTS  
The pipY protein product 
 PipY  was produced in E. coli from an expression plasmid and was obtained in 
pure form (Fig. 1A, inset). Similarly to the E. coli and yeast COG0325 gene products, 
YggS and YBL036C, [12,13,19], PipY was monomeric, judged from its behaviour in 
size exclusion chromatography assays (Fig. 1A). As expected for a protein forming a 
protonated Schiff base with PLP [33], pure PipY was yellow due to a broad optical 
absorption peak having its maximum absorption at ~425 nm (Fig. 1B, black continuous 
line), a longer wavelength than the maximum for free PLP (Fig. 1B, dotted line). PipY 
incubation with excess PLP, followed by removal of the PLP excess by centrifugal gel 
filtration [30] increased the size of the 425-nm peak (Fig. 1B, dashed line), as if the pure 
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protein was incompletely saturated with PLP, perhaps because of partial dissociation of 
PLP during protein isolation and storage. In fact, prolonged PipY storage (several 
months) decreased the height of the 425-nm peak (Fig. 1B, grey line), as expected for 
PLP dissociation with time. Titration with PLP of this aged protein restored maximal 
absorbance with a KD value for PLP of ~30 µM (Fig. 1C). As is typical for protein-
bound PLP [34], the 425-nm peak disappeared with the addition of DCS (Fig. 1D), 
while absorbance at shorter wavelength (around 335 nm) increased. Titration of the 
decrease in absorbance at 425 nm versus DCS concentrations (Figs. 1D and 1E) yielded 
a KD for DCS in the mM range, two to three orders of magnitude higher than KD values 
for PLP-containing proteins that bind DCS as an analogue of an amino acid substrate 
(the case for alanine racemase [15]). This low affinity for DCS excludes specific 
binding of this antibiotic to PipY, in agreement with the reported lack of alanine 
racemase activity of PipY [11] and of the COG0325 gene products of other species [13].  
 
Overall characteristics of crystalline PipY 
 PipY crystal structures were determined at ~1.9 Å resolution with and without 
PLP (PipY-PLP and PipY-Apo, respectively; Table 1). No electron density that could 
correspond to D-Ala or DCS was observed in the crystals, despite the fact that these 
compounds were present at 10 mM concentrations in the respective crystallization 
solutions (see Materials and Methods). Each crystal had two protein chains in the 
asymmetric unit. These chains were related by twofold non-crystallographic symmetry. 
The small contact surfaces (~5% of the exposed surface) and the predictions of the 
PISA server (www.ebi.ac.uk/pdbe/pisa/) did not support a homodimeric nature of PipY 
in solution, agreeing with the size exclusion chromatography results that showed that 
PipY is a monomer (Fig. 1A). 
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 Except for the initial and final 2-3 residues and the C-terminal His6-tag, the 
entire polypeptide chains were visible in the crystal structures. In addition, one PLP 
molecule was found binding per chain in the PipY-PLP crystal. Both monomers in each 
asymmetric unit were essentially identical (r.m.s.d. <0.6 Å, Supplementary Table S1), 
with somewhat lower identity when PLP-containing and PLP-lacking PipY molecules 
were compared (r.m.s.d. 0.62-0.98 Å, Supplementary Table S1). There was high 
similarity with the reported structure [19] of the yeast COG0325-encoded protein 
YBL036C or with the structures of another three COG0325 products from other 
bacteria that are deposited in the PDB (Supplementary Table S1; r.m.s.d. 1.29-1.75 Å; 
and Supplementary Fig S2A).  
 
The structure of PipY  
 PipY has (Fig. 2A) the characteristic type-III fold of PLP-dependent enzymes 
[19,35], a modified TIM barrel [36] having an extra N-terminal α-helix preceding the 
first of the eight β/α repeating units and lacking the helix of the last repeat. Unlike the 
paradigms of this fold, alanine racemase, ornithine decarboxylase and broad specificity 
amino acid racemase [37-39], all of them composed of two-domain subunits forming 
homodimers, PipY is a single-domain monomer consisting exclusively of the barrel 
domain (Supplementary Fig. S2A). This is also the case for the highly similar structures 
previously reported for YBL036C [19] or deposited in the PDB for another three 
bacterial COG0325 proteins (Supplementary Table S1). All these COG0325 protein 
structures have a one-turn imperfect α helical extension of the C-terminal β-strand 
(helix 9, Fig. 2A and Supplementary Fig. S2A). This extension binds the phosphate of 
PLP (see below). However, PipY differs from all the other COG0325-encoded protein 
products of known structure in the length of the first α-helix (Supplementary Fig. S2), 
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which in PipY spans less than three full turns, while in all these other proteins is much 
longer on both the N- and C-terminal ends of this helix, which spans up to 6 turns (Fig. 
2B). Perhaps this helix, which is lacking in canonical TIM barrels, could be involved in 
interactions with other proteins, with specific requirements for COG0325 proteins of 
different species. 
 
PLP binding  
 PLP sits towards the centre of the barrel, on the C-edge side of the parallel β-
sheet (Fig. 2A). It is found in the same site and orientation as in yeast YBL036C and in 
the deposited structures of COG0325 proteins. This location is the same that is found in 
the PLP enzymes presenting the PLP type III fold (Supplementary Figs. S2A-C). 
However, in PipY and the other COG0325 proteins of known structure the PLP is much 
more accessible than in the type III fold PLP enzymes [37-39]. In these dimeric 
enzymes the cofactor is shielded by the two-domain architecture and by the other 
subunit, being accessible only through a tunnel (not shown). The exposed PLP of PipY 
and of other COG0325 proteins should facilitate PLP exchange with other molecular 
partners. The PLP forms a Schiff base with Lys26 (Fig. 2C; and Supplementary Fig. 
S2C). Its phosphate is anchored via six hydrogen bonds on helix 9 (residues Gly212 and 
Thr213) and on the β7-α8 turn (Ser195 and, indirectly through water, Ser196). The 
cofactor makes other non-covalent interactions with six of the eight β/α repeats of the 
modified TIM barrel. Only β/α repeats 4 and 5 do not contact the PLP. The pyridoxal 
ring is partially sandwiched between Leu70 from β3 and Met194 from the β7-α8 turn, 
lying through its border on Arg210 from β8, with which an NH..N hydrogen bond is 
made. The exposed part of the pyridoxal ring makes contacts through its C2-methyl 
group with Met152 from β6, hydrogen bonding its C3-OH with Asn47 from β2, and 
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contacting Val24 of β1 via its C4 carbaldehyde and C5 hydroxymethyl groups. Except 
for the indirect interaction with Ser196 (Fig. 2C), all PLP interactions found in PipY are 
present in the other COG0325 structures, either with identical or conservatively 
replaced residues (Supplementary Fig.S2A).  
 
Changes associated with PLP binding in the context of a role of PipY in PLP 
homeostasis 
 Our determination of the structures of PLP-bound and PLP-free forms of PipY 
allowed characterization of the changes associated with PLP binding (Fig. 2D). These 
changes are not large, as shown by the modest r.m.s.d. increase when comparing PipY-
PLP and PipY-Apo (Supplementary Table S1). The largest changes are experienced by 
helix 9 (Fig. 2D), which is displaced towards the PLP phosphate that anchors on it. This 
helix drags in its movement the residues following it, which are displaced by up to 4.5 
Å. Helices 1 and 2 are also dragged towards the phosphate, while Ser195 and the β7-α8 
loop are displaced by the phosphate, with concomitant small displacement of helix 8, 
which drags with it helix 7 and the β6-α7 loop, and even helix 6 and the β5-α6 loop.  
 The movement of helix 9 might be the best candidate for triggering the PLP 
exchange required for the proposed role of PipY in PLP homeostasis [11-14,17,18]. Due 
to its exposed nature helix 9 could interact with other macromolecular players, acting as 
a trigger for PLP exchange, since a change in the position of helix 9 could importantly 
weaken PLP binding to PipY, given the PLP-anchoring role of this helix. 
 




 Recently, vitamin B6-dependent epilepsy was reported in association with null 
mutations in the human COG0325 gene PROSC [17,18]. However, some patients 
carried the missense PROSC mutations Pro87Leu and/or Arg241Gln, two mutations for 
which a loss-of-function effect was at best hypothetical [18]. In addition, there was no 
correspondence between the degree of clinical severity attributed to each of these 
mutations on the basis of the observations on the patients [18] and the ability of each 
mutant form to complement the increased pyridoxine toxicity phenotype of the yggS
- 
E.coli mutant [17]. Since the PROSC Pro87 and Arg241 residues are conserved in 
S.elongatus PipY (respective PipY counterparts, Pro63 and Arg210, Supplementary Fig. 
S1), we investigated the effects of the corresponding PipY mutations on recombinantly 
produced PipY as an approximation to the effects of PROSC mutations. Both mutant 
proteins could be purified (Fig. 3A, bottom panel) and were monomeric (determined by 
size exclusion chromatography, data not shown). The Pro63Leu mutation did not 
negatively affect any of the parameters assessed: yield (Fig. 3A, top panel), thermal 
stability (Fig. 3B), proper fold of the pure protein (estimated by CD, Fig. 3C) and PLP 
content (assessed by the absorption spectrum, Fig. 3D). The latter was to be expected, 
since Pro63 sits on the opposite face of the TIM barrel than PLP (Fig. 2A) and, 
therefore, the mutations of this residue should not directly hamper PLP binding. In 
contrast, the Arg210Gln mutant, also obtained in pure (Fig. 3A, bottom panel) and well-
folded form (Fig. 3C) was produced in quite low yield (Fig. 3A, top panel), exhibited 
decreased thermal stability (nearly 5ºC decrease, Fig. 3B) and had little if any PLP, 
judged from its low optical absorption in the 425 nm region (Fig. 3D). This last 
observation fits the fact that the mutation affects the invariant arginine shown by the 
structure to run parallel to the buried border of the pyridoxal ring, with which it makes 
an NH..N hydrogen bond (Fig. 2A,C). Our findings explain the results of 
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complementation assays for the Pro87Leu and Arg241Gln PROSC mutants [17] and the 
disease-causality of the Arg241Gln mutation (see Discussion)  
 
DISCUSSION 
 The complementation of yggS
-
 E.coli by COG0325 genes of other species 
[12,13,17] and  the phenotypic similarities of this E.coli mutant and of the S.elongatus 
pipY
-
 mutant [11] are strong indications that the function of COG0325 genes is 
conserved  across phyla. The alleviation by PLP or by vitamin B6 supplementation of 
the alterations observed in these mutants [11-14], best illustrated by the vitamin B6 
dependence of the epilepsy due to PROSC deficiency [17,18], indicates that this 
conserved function is related to PLP, in line with the fact that COG0325 products are 
PLP-containing  proteins. Yet, previous work [11-13] has not favoured an enzymatic 
role of COG0325 proteins. In our own work, we have failed to generate crystals of PipY 
bound to D-Ala or to DCS despite extensive crystallization attempts with these 
compounds. These two ligands have been found binding in crystals of the structurally 
similar alanine racemase [40]. Furthermore, as exemplified in the PipY structure, 
COG0325 proteins lack key constant and obligatory features of type III-fold PLP 
enzymes [35]. These missing traits include the dimeric character, the presence of a 
second domain and the existence of an invariant substrate-binding arginine (Arg129 of 
Ala racemase, Supplementary Figs. S2A,C) and of a negative charge that stabilizes this 
arginine [37-41]. Thus, COG0325 proteins are believed to be involved in PLP 
homeostasis rather than being catalysts [11-14,17,18]. 
 A PLP-homeostatic role would be instrumental to prevent the toxicity of free B6-
vitamers [13,42, and  see 17] and would imply that COG0325 proteins deliver PLP to 
the apoenzymes of PLP-dependent enzymes. Such  role fits: i) the observations of 
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increased toxicity of pyridoxine with yggS
-
 E. coli [12,13] and of pyridoxine and  PLP-
targeting antibiotics with pipY
-
 S. elongatus  [11]; ii) the interactions of these traits with 
the supply of amino acids to these bacterial mutants [11-13]; iii) the observation of  
pleiotropic amino acid metabolism changes in COG0325 mutants [12-14,16-18]; iv) the 
synthetic lethality caused in S. elongatus by the pipY/cysK double mutation [11]; and v) 
particularly, the finding of amino acid levels in the cerebrospinal fluid of a patient with 
PROSC deficiency that are highly suggestive of multiple transaminase deficiency [18]. 
In line with a homeostatic role of PipY, in the structures of PipY (present data) and of 
other COG0325 proteins ([19], and see PDB files given in Supplementary Table S1) 
PLP is exposed as if it was poised for transfer. Furthermore, the relatively large changes 
in the orientation of the outwards-protruding helix 9 depending on the presence or 
absence of PLP, taken together with the key role of this helix in PLP anchoring, renders 
this helix an obvious candidate for being a trigger that could be operated by partners to 
weaken the interactions of COG0325 proteins with PLP, promoting PLP transfer.  
 The alternative possibility that COG0325 proteins, although not catalytic by 
themselves, could be subunits of hypothetical heterodimeric PLP enzymes in which the 
COG0325 subunit would act as a common PLP-containing module appears unlikely. 
The pleiotropic metabolic effects of the null COG0325 gene mutations demand multiple 
alternative partners for the COG0325 protein. It would be unlikely not to detect any of 
these partners in yeast-two-hybrid assays using PipY as the bait, but, in fact, no partner 
was detected [11]. Furthermore, the increased amino acid levels in the cerebrospinal 
fluid of a PROSC-deficient patient [18] fitted multiple transaminase deficiency. 
However, transaminases do not utilize for binding PLP the modified TIM barrel fold 
used by COG0325 proteins [35]. Similarly, a role of COG0325 in the regulation of a 
specific PLP enzyme, as exemplified for ornithine decarboxylase with its 
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enzyme/antizyme/antizyme inhibitor system [43], cannot be excluded, but, again, 
appears unlikely, largely because it would not fit the multi-target pleiotropy reflected in 
the metabolic phenotypes of COG0325 mutants. 
 Strong support for a PLP homeostatic role of COG0325 proteins was provided 
by observations made in vitamin B6-dependent epilepsy associated to PROSC mutations 
[17,18]. By using PipY as a model of PROSC, we attempted here to shed light on why 
the PROSC Pro87Leu mutant complemented and the Arg241Gln mutant did not 
complement the pyridoxine toxicity phenotype of an E.coli yggS
-
 strain [17]. The 
abundant production in E.coli of PLP-carrying Pro63Leu PipY could explain the 
complementation observed with the PROSC Pro87Leu mutant [17]. In contrast, lack of 
complementation would be expected for the poorly produced and PLP-lacking 
Arg210Gln mutant of PipY, as observed for the corresponding human PROSC mutant  
Arg241Gln [17], in line with the prior observation that there was no complementation 
by YggS when it carried a mutation that made it unable to bind PLP [13]. Concerning 
disease-causation and clinical severity, the lack of bound PLP and the decreased 
stability and yield of PipY carrying the Arg210Gln mutation clearly support a disease-
causing role of the corresponding Arg241Gln PROSC mutation, in agreement with the 
finding of this last mutation in patients with vitamin B6-dependent epilepsy. However, 
the PROSC deficiency due to the Arg241Gln mutation may be partial if the mutant can 
still bind PLP at increased concentrations of this cofactor, what could explain the 
relatively mild clinical severity associated with this mutation [18]. In contrast to the 
Arg210Gln PipY mutant, the PipY Pro63Leu mutant that mirrors the PROSC Pro87Leu 
mutant appeared normal. Thus studies using the PROSC Pro87Leu mutant itself 
expressed in human cells might be necessary to test experimentally the disease-
causation and clinical severity attributed to this mutation [18]. In any case, it is 
17 
 
interesting that three of the six missense PROSC mutations observed thus far in patients 
with vitamin B6-dependent epilepsy replace proline by leucine or the reverse 
(Supplementary Fig. S2A) [17,18]. Given the structural uniqueness of proline as a 
protein amino acid, it is conceivable that these changes could lead to increased PROSC 
misfolding, raising the possibility of using pharmacological chaperones to try to 
alleviate the deleterious effects of these missense mutations.   
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Fig. 1. PipY properties. (A) Size exclusion chromatography of pure PipY  with elution 
monitored as UV absorption (bottom) and plotted semilogarithmically (top) together with 
the elution positions of molecular mass standards (closed circles). The open circle, 
corresponding to PipY, has been placed at the intersection of the PipY elution position and 
its sequence-deduced mass. The protein standards used and their masses (in parenthesis, in 
kDa) were: Enterococcus faecalis carbamate kinase (71.3) [44], bovine serum albumin 
(66.4), E. coli N-acetyl-L-glutamate kinase (54.3) [45], chicken ovalbumin (42.7), S. 
elongatus PII (37.2) [46], Pseudomonas aeruginosa PII (36.9) (our own unpublished data), 
bovine erythrocyte carbonic anhydrase (29), soybean trypsin inhibitor (21.5), cow
 
s 
lactalbumin (14.2), pancreatic ribonuclease A (13.7) and horse heart cytochrome C (12.3).  
Inset, SDS-PAGE of pure  PipY (St, protein standards of the indicated masses). (B) Optical 
absorption spectrum of PipY, freshly prepared (black continuous line), after aging for several 
months (grey continuous line), or following a 15-min incubation of 2 mg/ml PipY with 0.34 
mM PLP, followed by excess PLP removal by centrifugal gel filtration [30] (broken line, 
large trace). Spectra are normalized relative to the absorption at 280 nm. For comparison, the 
spectrum of PLP, normalized to a maximum absorbance of 0.3, is shown (dotted line). (C) 
Influence of added PLP on the height of the protein-bound PLP peak of 0.66 mg/ml of aged 
PipY. (D, E) Influence of variable DCS concentrations on the absorption spectrum of PipY 
(0.91 mg/ml, incubated with 0.34 mM PLP and then freed from unbound PLP by centrifugal 





































































Figure 2. PipY structure. Panels A and C are stereo 
views. Beta strands are labeled with numbers. Helices are 
numbered also with numbers preceded by an α. When using 
sticks representation (always the case for PLP), O, N, S and P 
atoms are coloured red, blue, yellow and orange, respectively, 
and C atoms are yellow for PLP and grey for the protein. (A) 
Cartoon representation of the structure of PipY complexed with 
PLP. Helices are pink and strands are blue. Red spheres mark 
the locations of Pro63 and Arg210, which correspond to human 
PROSC Pro87 and Arg241. (B) Cartoon side views (90º 
rotation around the X axis, relative to the view in panel A, with 
the C-edge of the β sheet pointing to the top) of PipY and the 
yeast COG0325 gene product YBL036C (PDB 1CT5), to 
highlight the differences in the length of helix 1, which is 
deeply colored. (C) The PLP binding site. Side-chains are 
shown in sticks and labeled in single letter notation. The grid 
around the PLP-Lys26 adduct shows the Fo-Fc omit electron 
density map for this adduct at 2.5 σ. Broken red lines represent 
hydrogen bonds of PLP with the protein (D) PipY movements 
upon PLP binding shown by superimposing PipY-Apo (pink) 
and PipY-PLP (gray) in cartoon representation. Selected 























































































































) D C 
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Figure 3. Comparisons between wild-type and Pro63Leu and Arg210Gln mutants of PipY. 
(A) Yield (top; mean
 
SE; n ≥ 2) and purity (bottom; coomassie-stained SDS-PAGE, 15% gel) of 
the final protein preparations. (B) Thermal stability of the wild-type (closed circles) and the two 
mutants (open circles), estimated in thermofluor assays (see Materials and Methods). Buffer, pH 
and protein concentrations were the same for both panels, but the solution contained, in 
addition, 0.5 M NaCl and 20 mM imidazole (left panel) or 16 mM NaCl and 1mM DTT (right 
panel). The broken lines mark for each protein form the temperature at which the fluorescence 
change is 50% of the maximum.  (C) CD spectra to exclude gross misfolding of the mutants. (D) 
Optical absorption spectrum to show that the Arg210Gln mutant lacks the peak of bound PLP. 
Spectra are the average of ≥ 2 preparations. They are normalized relative to the absorption at 
280 nm.  
PROSC     MWRAGSMSAELGVGCALRAVNERVQQAVARRPRDLPAIQPRLVAVSKTKPADMVIEAYGH 60 
PipY      ----------------MAQIAERLASL----RSQL-PPSVQLIAVSKNHPAAAIREAYAA 39 
                          :  : **: .       :*   . :*:****.:**  : ***.  
                         α3         L     β3 
PROSC     GQRTFGENYVQELLEKASNPKILSLCPEIKWHFIGHLQKQNVNKLMAVPNLFMLETVDSV 120 
PipY      GQRHFGENRVQEAIAKQA--ELTDL-PDLTWHLLGKLQSNKARKAVE--HFDWIHSVDSW 94 
          *** **** *** : * :  ::. * *::.**::*:**.::..* :   ::  :.:***  
 
PROSC     KLADKVNSSWQRKGSPERLKVMVQINTSGEESKHGLPPSETIAIVEHINAKCPNLEFVGL 180 
PipY      ALAERLDRIAGELGRSPKLC--LQVKLLPDPNKAGWDPADLRAELPQL-SQLQQVQIRGL 151 
           **::::    . *   :*   :*::   : .* *  *::  * : :: ::  :::: ** 
 
PROSC     MTIGSFGHDLSQGPNPDFQLLLSLREELCKKLN---IPADQVELSMGMSADFQHAVEVGS 237 
PipY      MVIAPLGLTAAET-----QALFAQARTFAAELQQQAPQLRLTELSMGMSSDWPLAVAEGA 206 
          *.*. :*   ::      * *::  . :. :*:        .*******:*:  **  *: 
          β8 Q    α9 
PROSC     TNVRIGSTIFGERDYSKKPTPDKCAADVKAPLEVAQEH 275 
PipY      TWIRVGTQLFGPRSL----------------------- 221 
          * :*:*: :** *.                         
Supplementary Figure S1. Clustal ω (www.ebi.ac.uk) sequence alignment of S. elongatus 
PipY and human PROSC, indicating above the piled sequences the epilepsy-associated  
mutations Pro87Leu and Arg241Gln [17,18] that have been introduced here into the 
corresponding positions of PipY. Secondary structure elements surrrounding the mutated 
residue are indicated in PipY by double underlining (strands) or ondulating underlining 
(helices), identifying these elements above the sequences. Below the sequences, asterisks 
mark invariance, and double and single dots indicate higher and lower strengths of residue 









































































































Supplementary Figure S2 
                         α1                        β1▼ ▼      α2             β2         α3      
PipY        1 ----MAQIAERLASLRSQL------------PPSVQLIAVSKNHPAAAIREAYAA---GQRHFGENR--VQEAIAKQAELT--  60 
YBL036C     8 DEDRKTQLIAQYESVREVVNAEAKNVHVNENASKILLLVVSKLKPASDIQILYDH---GVREFGENY--VQELIEKAKLLP--  83 
COG0325BA  18 DDARAREITDGVHRVLDRIAAAEEQ--AGREAGSVRLLAATKTRDIGEIMAAIDA---GVRMIGENR--PQEVTAKAEGLARR  93 
YggS        1 ----MNDIAHNLAQVRDKISAAATR--CGRSPEEITLLAVSKTKPASAIAEAIDA---GQRQFGENY--VQEGVDKIRHFQEL  72 
COG0325AT   1 ----MMEIEARLEDVRQRIADVAEK--SGRKAADVALVAVSKTFDAEAIQPVIDA---GQRVFGENR--VQEAQGKWPALKEK  72 
ODC        47 -----DILKKHLRWLKALP--------------RVTPFYAVKCNDSRAIVSTLAAI--G-TGFDCAS--KTEIQLVQG----- 100 
Ala Racem  12 ------ALRHNLQRLREL-------------APASKMVAVVKANAYGHGLLETARTLPDADAFGVAR--LEEALRLRA-----  68 
AA Racem   49 -------LGQFQSNIEQFKSH---------MNANTKICAIMKADAYGNGIRGLMPTIIAQGIPCVGVASNAEARAVRE----- 110 
                                                     ▲ ▲     
                                      β3▼         α4          β4        α5                β5  
PipY       61 -----------------DLPDLTWHLLGKL-QSNKARKAVEH--FDWIHSVDSWALAERLDRIAGELGRS-PKLCLQVKLLPD 122 
YBL036C    84 -------------------DDIKWHFIGGL-QTNKCKDLAKVPNLYSVETIDSLKKAKKLNESRAKFQPDCNPILCNVQINTS 146 
COG0325BA  94 CAERGFSLGVAGAAPDAAAEHIPFHLIGQL-QSNKIGKVL--PVVDTIESVDSIDLAEKISRRAVARGIT---VGVLLEVNES 170 
YggS       73 -----------------GVTGLEWHFIGPL-QSNKSRLVAEH--FDWCHTIDRLRIATRLNDQRPAELPP---LNVLIQINIS 132 
COG0325AT  73 ------------------TSDIELHLIGPL-QSNKAADAVAL—-FDVVESIDREKIARALSEECARQGRS---LRFYVQVNTG 131 
ODC       101 ----------------LGVPAERVIYANPCKQVSQIKYAAS--NGVQMMTFDSEIELMKVARA-----HPKAKLVLRIATDDS 160 
Ala Racem  69 -----------------GGITKPVLLLEGFFDARDLPTISA----QHFHTAVHNEEQLAALEEASLDE----PVTVWMKLDTG 126 
AA Racem  111 -----------------SGFKGELIRVRSASLSEMSSALDL----NIEELIGTHQQALDLAELAKQS---GKTLKVHIALNDG 169 
                                        ▲                                                   *     
                                α6          β6                    α7                      β7          
PipY      123 PN--KAGWD---PADLRAELPQLSQLQQVQIRGLMVIAPLGL--TAAETQALFAQARTFAAELQQQA---PQLRLTELSMGM- 194 
YBL036C   147 HEDQKSGLNNEAEIFEVIDFFLSEECKYIKLNGLMTIGSWNVSHEDSKENRDFATLVEWKKKIDAKF-----GTSLKLSMGM- 223 
COG0325BA 171 GEESKSGCD---PAHAIRIAQKIGTLDGIELQGLMTIGAHVHD--ETVIRRGFSHLRKTRDLILAS-GEPGTDRCRELSMGM- 246 
YggS      133 DENSKSGIQ---LAELDELAAAVAELPRLRLRGLMAIPAPESE-YVRQFEVARQMAVAFAGLKTR------YPHIDTLSLGM- 204 
COG0325AT 132 LEPQKAGID---PRETVAFVAFCRDELKLPVEGLMCIPPAEENP-----GPHFALLAKLAGQCG----------LEKLSMGM- 195 
ODC       161 KAVCRLSVKFGATLKTSRLLLERAKELNIDVIGVSFHVGSGCTDPDTFVQAVSDARCVFDMATEV------GFSMHLLDIGGG 237 
Ala Racem 127 M--HRLGVRPEQAEAFYHRLTQC--KNVRQPVNIVSHFARADEPKCGATEKQLAIFNTFCEG-----------KPGQRSIAA- 193 
AA Racem  170 G-MGRNGID-MTTEAGKKEAVSIATQPSLSVVGIMTHFPNYNADEVRAKLAQFKESSTWLMQQ-----ANLKREEITLHVAN- 244 
                  ▲                               ▲                                                                   
 
                         α8                      β8▼  α9 
PipY       195 -------SSDWPLAVAEG---------------ATWIRVGTQLFGPRSL------- 221 
YBL036C    224 -------SADFREAIRQG---------------TAEVRIGTDIFGARPPKNEARII 257 
COG0325BA  247 -------TGDMELAIAEG---------------STIVRVGTAIFGERAFI------ 274 
YggS       205 -------SDDMEAAIAAG---------------STMVRIGTAIFGARDYSKK---- 234 
COG0325AT  196 -------SGDFETAVEFG---------------ATSVRVGSAIFGSRAENLYF--- 226 
ODC        238 FPGSEDTKLKFEEITSVINPALDKYFPSDSGV-RIIAEPGRYYVASA--------- 283 
Ala Racem  194 -------SGGILLWPQS---------------HFDWVRPGIILYGV---------- 217 
AA Racem   245 -------SYTALNVPEAQ---------------LDMVRPGGVLFGD---------- 268 







Supplementary Figure S2. Sequence and structural comparisons of PipY with 
other proteins. (A) Structure-aided sequence alignment of the five COG0325 gene 
products of known structure (S. elongatus PipY and the products of yeast, 
Bifidobacterium adolescentis, E. coli and Agrobacterium tumefaciens, abbreviated 
PipY, YBL036C, COG0325BA, YggS and COG0325AT, with PDB file identifiers 
5NM8, 1CT5, 3CPG, 1W8G and 3R79, respectively) and of the TIM barrel 
domains of mouse ornithine decarboxylase (ODC; PDB file 7ODC), E. coli alanine 
racemase (Ala Racem, PDB 2RJG) and Vibrio cholerae broad specificity amino 
acid racemase (AA Racem; PDB 4BEU). Residues conserved or conservatively 
replaced in at least 5 of the 7 aligned sequences are highlighted by black shadowing 
over white lettering. When the conservation is restricted to the 5 COG0325 
products or to the 3 enzymes, the residues are highlighted yellow and green, 
respectively. Horizontal arrows (in light blue) and rectangles (pinkish) under each 
sequence mark β strands and α helices, respectively, with labelling of these 
secondary structure elements at the top of the alignment (blue and pink labels). The 
triangles at the top and bottom signal residues that make contacts with PLP in the 
COG0325 products and the enzymes, respectively, being blue for the Shiff base-
making lysine, arrow-shaped an green-lined for phosphate-interacting residues, 
black if the interaction is conserved in all the aligned sequences, or yellow or red if 
conserved only in COG0325 products or the enzymes, respectively. In addition, 
yellow and red lettering is used in some occasions to confirm the interaction of a 
given residue with PLP when the interaction is not fully conserved. The red asterisk 
denotes the lysine that is carboxylated in Ala racemase. The curved small arrows 
and the adjacent mutations (shown in single letter code) above the PipY sequence 
indicate the corresponding single amino acid changes found in vitamin B6-
dependent epilepsy [17, 18]. (B) Stereo view of the superposition of the structures 
(backbone representation) of PipY-PLP (grey) and the barrel domain of  broad 
spectrum amino acid racemase (green; PDB entry 4BEU), alanine racemase (blue, 
2RJG) and ornithine decarboxylase (pink, 7ODC). The bound PLP molecules are 
shown in sticks representation and are coloured as the corresponding protein chain. 
Beta strands are  labeled with numbers while helices are labelled with an α 
followed by a number. (C) Detailed stereo view (sticks representation) of the 
superimposed PLP binding sites of PipY-PLP (black) and of the barrel domains of 
broad spectrum amino acid racemase (green; PDB 4BEU), alanine racemase 
(orange, 2RJG) and ornithine decarboxylase (pink, 7ODC). O, N, S and P atoms are 
coloured red, blue, yellow and orange, respectively. Residue labels are in single 
letter amino acid code and are in the same color as the corresponding structures. 
The pink asterisk denotes that lysine 122 is carboxylated in alanine racemase [41]. 
The green sphere is the Cl- anion in broad spectrum amino acid racemase [39]. 
Tyr389 of ODC belongs to the other domain of the same subunit of this enzyme. 
Not shown in the figure because they obliterate the view of other residues are 
Tyr299 and Tyr255 from the second domain of the other subunit of amino acid 
racemase and alanine racemase, respectively. These residues extend from the front 
of the figure towards the O atom bound to the C3 atom of the pyridoxal ring, 




The two chains in the same asymmetric unit are distinguished by the letters A and B. B. adolescentis, 
Bifidobacterium adolescentis; A. tumefaciens, Agrobacterium tumefaciens; AA, amino acids. The alanine 
racemase, broad spectrum amino acid racemase and ornithine decarboxylase are from E. coli, Vibrio 
cholerae and mouse, respectively. Protein DataBank accession numbers are given between parentheses. 
Except in the case of the protein from B. adolescentis, which contained no PLP and thus was compared 
with the monomers of PipY-Apo, all other proteins contained  PLP and have been compared with PipY-
PLP. In the cases of racemases and ornithine decarboxylase only the result of the best superimposition of 




Supplementary Table S1. Degree of similarity among the structures of PipY 
monomers studied here, and with the structures of other COG0325 gene products, 
and of TIM barrel domains of amino acid racemases and ornithine decarboxylase. 
 
 
Root mean square deviation for the superimposition of the 
indicated number of Cα atomsa  
(Å / number Cα atoms) 
 
 PipY-Apo A PipY-Apo B PipY-PLP A PipY-PLP B 
PipY-Apo B 0.59/215 - - - 
PipY-PLP A 0.90/213 0.62/215 - - 
PipY-PLP B 0.98/210 0.70/212 0.39/212 - 
COG0325  yeast YBL036C (1CT5) - - 1.63/195 1.61/194 
COG0325  E. coli  YggS (1W8G) - - 1.50/205 1.52/205 
COG0325  B. adolescentis  (3CPG) 1.75/202 1.69/202 - - 
COG0325  A. tumefaciens  (3R79 A) - - 1.29/199 1.42/196 
Alanine racemase (2RJG) - - 2.39/191 - 
Broad spectrum AA racemase (4BEU) - - - 2.31/200 
Ornithine decarboxylase  (7ODC) - - 2.60/186 - 
